Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of FH-TCR Tᴍsʟɴ in Metastatic Pancreatic Ductal Adenocarcinoma
NCT04809766Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of adverse events at 4 weeks and Dose limiting toxicities at 21 days. Started Dec 2021; status: terminated.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04809766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809766.